booker new-jersey pharma wall-street newark poverty drug-pricing
related: _Cory Booker Master Profile PhRMA Pfizer Johnson & Johnson Goldman Sachs
donors: PhRMA Pfizer Johnson & Johnson Goldman Sachs
The New Jersey Pharma Pipeline
New Jersey is the pharmaceutical industry’s home state: Johnson & Johnson (New Brunswick), Merck (Rahway), and dozens of pharmaceutical companies maintain headquarters or major operations in the state. Booker’s New Jersey base makes pharmaceutical industry engagement unavoidable — the industry employs tens of thousands of New Jerseyans and is a major contributor to the state’s economy and tax base.
Booker’s pharmaceutical donor relationships have created his most damaging political moment: his 2017 vote against the Klobuchar-Sanders amendment that would have allowed importation of prescription drugs from Canada. Booker was one of 13 Democrats who voted against the amendment, citing “safety concerns” about imported drugs — a pharmaceutical industry talking point. The vote — cast by a senator from the pharmaceutical industry’s home state — crystallized the Two-Audience Problem: Booker campaigns as a progressive champion of the poor while voting to protect the pharmaceutical industry’s pricing monopoly.
The Newark Contradiction
Booker’s political origin story is Newark — one of the poorest cities in America (28% poverty rate). He was elected mayor in 2006 and used Newark’s challenges as the narrative foundation for his political career: poverty, criminal justice, educational inequality. But Newark’s poverty exists within New Jersey — a state where the pharmaceutical, financial services, and insurance industries generate enormous wealth. The contradiction: Booker represents both the poorest city in the state and the industry donors whose business model contributes to the healthcare costs that impoverish his constituents.
Money
Booker’s 2017 vote against Canadian drug importation is the Two-Audience Problem made legislative: he told progressive voters he supported lower drug prices while voting to protect the pharmaceutical pricing monopoly that enriches his New Jersey donors. The “safety concerns” justification — the same talking point PhRMA deploys in every drug importation debate — provided cover for a vote that served the pharmaceutical industry’s $100+ billion annual US market. Booker has since supported other drug pricing measures, but the 2017 vote remains the clearest evidence that his donor relationships constrain his policy positions on the issue most relevant to his Newark constituency.
Sources
- Congress.gov: Cory Booker voting record on drug importation (Tier 1)
- OpenSecrets: Cory Booker pharmaceutical sector contributions (Tier 1)
- Senate.gov: Klobuchar-Sanders drug importation amendment vote (Tier 1)
- Ballotpedia: Cory Booker (Tier 3)
content-readiness:: ready